<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869634</url>
  </required_header>
  <id_info>
    <org_study_id>394080</org_study_id>
    <secondary_id>IIS RFA _Asmuth:TMC114HIV2029</secondary_id>
    <nct_id>NCT01869634</nct_id>
  </id_info>
  <brief_title>Mechanisms of Immune Reconstitution &amp; Reduced Immune Activation Following Darunavir-based ART</brief_title>
  <official_title>Mechanisms of Immune Reconstitution &amp; Reduced Immune Activation Following Darunavir-based ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to
      repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation
      (CD)4+ T-cell populations, normalization of systemic immune activation, and improved
      HIV-associated cardiovascular disease (CVD) risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale Infection with HIV causes significant morbidity and mortality, even among
      individuals who are virologically suppressed with combination anti-retroviral therapy (ART).
      ART is effective in prolonging life and enabling individuals who are HIV positive to live
      near-normal life spans. However, these individuals are increasingly developing a number of
      chronic diseases of aging, such as atherosclerotic cardiovascular disease (ASCVD). The
      proposed studies will examine the role of highly active antiretroviral therapy in restoring
      the mucosal immunity and the systemic effect on immune activation, bacterial translocation,
      and change in HIV-associated cardiovascular disease risk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CD4+ T-cells in the Lamina Propria/mm2 Before and After 12 Months of Therapy Compared to Age-matched Control Volunteers Without HIV</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>CD4+ T-cells in the lamina propria/mm2 before and after 12 months of therapy compared to age-matched control volunteers without HIV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Total Artery Diameter</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>computerized axial tomography angiography of the coronary arteries (CT-angio) before and after 12-months of Darunavir therapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Systemic Immune Activation</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in systemic immune activation, as measured by change in plasma cytokine levels (IL-6).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Human Immunodeficiency Virus Infection</condition>
  <arm_group>
    <arm_group_label>HIV positive naive to ART</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal control volunteers</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir with ritonavir and fixed-dose viread+emtricitabine daily</intervention_name>
    <arm_group_label>HIV positive naive to ART</arm_group_label>
    <other_name>darunavir (Prezista®) 800 mg with ritonavir 100 mg and Truvada® to be taken once daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to sign consent form

          -  Naïve to ART (remote ART use &gt;5 years will be considered on a case by case basis)

          -  No known GI or cardiovascular disease

          -  Between the ages of 18 and 60

          -  No active opportunistic infections or therapy for acute OI within 30 days of entry.
             Subjects can be on secondary prophylaxis with a history of AIDS defining illness.

          -  All women of childbearing potential (WCBP) must have a negative urine pregnancy test
             before any of the invasive or radiation exposure study procedures.

          -  Normal population should be free of chronic metabolic conditions such as diabetes,
             hypercholesterolemia, or coronary artery disease

          -  There are no CD4+ T-cell count or HIV plasma viral load restrictions.

        Exclusion Criteria:

          -  Abnormal coagulation parameters (PT&gt;1.2 upper limit of normal (ULN))

          -  Thrombocytopenia (platelet count &lt;50.000 within 6 weeks)

          -  Contra-indications to upper endoscopy or conscious sedation

          -  Anemia (&gt;grade 1 [appendix 1])

          -  Aspirin, ibuprofen, warfarin or other agents that interfere with the coagulation
             cascade are prohibited within 1 week of endoscopy.

          -  Renal insufficiency (serum Creatinine &gt;1.2 ULN)

          -  History of chronic proteinuria that could impact viread use.

          -  Allergy to contrast used for CT angiography

          -  Requirement to take medications that are contraindicated with study ART regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 1, 2013</study_first_submitted>
  <study_first_submitted_qc>June 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <results_first_submitted>December 18, 2018</results_first_submitted>
  <results_first_submitted_qc>February 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2020</results_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>systemic immune activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV Positive Naive to ART</title>
          <description>HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
darunavir with ritonavir and fixed-dose viread+emtricitabine daily</description>
        </group>
        <group group_id="P2">
          <title>Normal Control Volunteers</title>
          <description>HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV Positive Naive to ART</title>
          <description>HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
darunavir with ritonavir and fixed-dose viread+emtricitabine daily</description>
        </group>
        <group group_id="B2">
          <title>Normal Control Volunteers</title>
          <description>HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="31" upper_limit="51"/>
                    <measurement group_id="B2" value="37" lower_limit="33" upper_limit="47"/>
                    <measurement group_id="B3" value="37" lower_limit="32" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cells</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="215" lower_limit="150" upper_limit="260"/>
                    <measurement group_id="B2" value="460" lower_limit="370" upper_limit="530"/>
                    <measurement group_id="B3" value="310" lower_limit="210" upper_limit="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV viral load</title>
          <units>copies/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41032" lower_limit="20689" upper_limit="78805"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="41032" lower_limit="20689" upper_limit="78805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>lbs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187" lower_limit="153" upper_limit="200"/>
                    <measurement group_id="B2" value="194" lower_limit="176" upper_limit="210"/>
                    <measurement group_id="B3" value="191" lower_limit="170" upper_limit="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of CD4+ T-cells in the Lamina Propria/mm2 Before and After 12 Months of Therapy Compared to Age-matched Control Volunteers Without HIV</title>
        <description>CD4+ T-cells in the lamina propria/mm2 before and after 12 months of therapy compared to age-matched control volunteers without HIV.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>HIV negative participants underwent the procedures only once at Screening (entry). In the HIV group the comparison between before and after ART was done using a Wilcoxon signed-rank test.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive Naive to ART</title>
            <description>HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
darunavir with ritonavir and fixed-dose viread+emtricitabine daily</description>
          </group>
          <group group_id="O2">
            <title>Normal Control Volunteers</title>
            <description>HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD4+ T-cells in the Lamina Propria/mm2 Before and After 12 Months of Therapy Compared to Age-matched Control Volunteers Without HIV</title>
          <description>CD4+ T-cells in the lamina propria/mm2 before and after 12 months of therapy compared to age-matched control volunteers without HIV.</description>
          <population>HIV negative participants underwent the procedures only once at Screening (entry). In the HIV group the comparison between before and after ART was done using a Wilcoxon signed-rank test.</population>
          <units>cells / mm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="34" upper_limit="190"/>
                    <measurement group_id="O2" value="478" lower_limit="389" upper_limit="627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-months after ART</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" lower_limit="120" upper_limit="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison between HIV positive naïve to ART before and after ART has been done.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Wilcoxon signed-rank test. Paired samples.</non_inferiority_desc>
            <p_value>0.0025</p_value>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Total Artery Diameter</title>
        <description>computerized axial tomography angiography of the coronary arteries (CT-angio) before and after 12-months of Darunavir therapy</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>We compare wall thickness between HIV+ infected individuals and in the HIV group before and after 12-months of ART.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive Naive to ART</title>
            <description>HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
darunavir with ritonavir and fixed-dose viread+emtricitabine daily</description>
          </group>
          <group group_id="O2">
            <title>Normal Control Volunteers</title>
            <description>HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Total Artery Diameter</title>
          <description>computerized axial tomography angiography of the coronary arteries (CT-angio) before and after 12-months of Darunavir therapy</description>
          <population>We compare wall thickness between HIV+ infected individuals and in the HIV group before and after 12-months of ART.</population>
          <units>% of total artery diameter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="54" upper_limit="61"/>
                    <measurement group_id="O2" value="53" lower_limit="50" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-sample Wilcoxon rank-sum (Mann-Whitney) test</non_inferiority_desc>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison of coronary artery wall thickness before and after ART in the HIV infected participants.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Wilcoxon signed-rank test</non_inferiority_desc>
            <p_value>0.826</p_value>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Systemic Immune Activation</title>
        <description>Change in systemic immune activation, as measured by change in plasma cytokine levels (IL-6).</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive Naive to ART</title>
            <description>HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
darunavir with ritonavir and fixed-dose viread+emtricitabine daily</description>
          </group>
          <group group_id="O2">
            <title>Normal Control Volunteers</title>
            <description>HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systemic Immune Activation</title>
          <description>Change in systemic immune activation, as measured by change in plasma cytokine levels (IL-6).</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" lower_limit="1.42" upper_limit="2.15"/>
                    <measurement group_id="O2" value="0.66" lower_limit="0.50" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>comparison between groups (HIV+ vs HIV-)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Two-sample Wilcoxon rank-sum (Mann-Whitney) test</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Changes in systemic immune activation through IL6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.807</p_value>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HIV Positive Naive to ART</title>
          <description>HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
darunavir with ritonavir and fixed-dose viread+emtricitabine daily</description>
        </group>
        <group group_id="E2">
          <title>Normal Control Volunteers</title>
          <description>HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Asmuth, Professor of Medicine</name_or_title>
      <organization>University of California, Davis Health, Department of Internal Medicine</organization>
      <phone>916-734-8695</phone>
      <email>dasmuth@UCDAVIS.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

